{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:01:58Z","timestamp":1786989718182,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.gassur.2026.102358","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:47:39Z","timestamp":1770104859000},"page":"102358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity score\u2013matched analysis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2727-842X","authenticated-orcid":false,"given":"Takayuki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aletta","family":"Deranteriassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alykhan","family":"Premji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johathan","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar Joe","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Raldow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motaz","family":"Qadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Fernandez-Del","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Lillemoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.gassur.2026.102358_bib1","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2026.102358_bib2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1245\/s10434-011-2156-7","article-title":"Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease","volume":"19","author":"Bickenbach","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2026.102358_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","article-title":"FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience","volume":"18","author":"Faris","year":"2013","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.gassur.2026.102358_bib4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.gassur.2026.102358_bib5","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1245\/s10434-020-09391-9","article-title":"Outcomes of neoadjuvant chemotherapy versus chemoradiation in localized pancreatic cancer: a case-control matched analysis","volume":"28","author":"Chopra","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2026.102358_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/bjs\/znac002","article-title":"Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis","volume":"109","author":"Oba","year":"2022","journal-title":"Br J Surg"},{"issue":"8","key":"10.1016\/j.gassur.2026.102358_bib7","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdp015","article-title":"Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review","volume":"20","author":"Le Scodan","year":"2009","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.gassur.2026.102358_bib8","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.gassur.2026.102358_bib9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.hpb.2023.04.019","article-title":"Neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable pancreas adenocarcinoma: influence of vascular margin status and type of chemotherapy","volume":"25","author":"Palm","year":"2023","journal-title":"HPB"},{"issue":"4","key":"10.1016\/j.gassur.2026.102358_bib10","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/cancers15041252","article-title":"The timing of surgery following stereotactic body radiation therapy impacts local control for borderline resectable or locally advanced pancreatic cancer","volume":"15","author":"Lin","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.gassur.2026.102358_bib11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.hpb.2020.11.004","article-title":"Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer","volume":"23","author":"Zakem","year":"2021","journal-title":"HPB"},{"issue":"9","key":"10.1016\/j.gassur.2026.102358_bib12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1080\/0284186X.2019.1631472","article-title":"Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma","volume":"58","author":"Jiang","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.gassur.2026.102358_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2020.01.007","article-title":"Neoadjuvant treatment strategies for resectable pancreas cancer: a propensity-matched analysis of the National Cancer Database","volume":"143","author":"Xiang","year":"2020","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/j.gassur.2026.102358_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/COC.0000000000000947","article-title":"Multiagent chemotherapy followed by stereotactic body radiotherapy versus conventional radiotherapy for resected pancreas cancer","volume":"45","author":"Mokhtech","year":"2022","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2026.102358_bib15","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.surg.2017.11.027","article-title":"Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: the impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy","volume":"163","author":"Blair","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.gassur.2026.102358_bib16","series-title":"NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma 2023. Version 2","author":"National Comprehensive Cancer Network","year":"2023"},{"issue":"3","key":"10.1016\/j.gassur.2026.102358_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/jclinpath-2016-203947","article-title":"Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study","volume":"70","author":"Kalimuthu","year":"2017","journal-title":"J Clin Pathol"},{"issue":"2","key":"10.1016\/j.gassur.2026.102358_bib18","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.gassur.2026.102358_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2559.2009.03376.x","article-title":"Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin","volume":"55","author":"Campbell","year":"2009","journal-title":"Histopathology"},{"issue":"25","key":"10.1016\/j.gassur.2026.102358_bib20","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.gassur.2026.102358_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1748-717X-8-44","article-title":"Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety","volume":"8","author":"Gurka","year":"2013","journal-title":"Radiat Oncol"},{"issue":"11","key":"10.1016\/j.gassur.2026.102358_bib22","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2020.0785","article-title":"Association between surgical approach and major surgical complications in patients undergoing total hip arthroplasty","volume":"323","author":"Pincus","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.gassur.2026.102358_bib23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.gassur.2026.102358_bib24","doi-asserted-by":"crossref","first-page":"7879","DOI":"10.1002\/cam4.3330","article-title":"Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: a multicenter case-control study (PAULA-1)","volume":"9","author":"Arcelli","year":"2020","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.gassur.2026.102358_bib25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102358_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of marginal local failure in a Phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer","volume":"42","author":"Kharofa","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102358_bib27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jamasurg.2013.1058","article-title":"Concomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10,206 patients","volume":"148","author":"Worni","year":"2013","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.gassur.2026.102358_bib28","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/jamaoncol.2020.3537","article-title":"Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment","volume":"6","author":"van Roessel","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102358_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamasurg.2022.5696","article-title":"Evaluation of adjuvant chemotherapy survival outcomes among patients with surgically resected pancreatic carcinoma with node-negative disease after neoadjuvant therapy","volume":"158","author":"Hammad","year":"2023","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.gassur.2026.102358_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamaoncol.2022.5808","article-title":"Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy","volume":"9","author":"Sugawara","year":"2023","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102358_bib31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11605-022-05476-w","article-title":"Tailoring adjuvant chemotherapy to biologic response following neoadjuvant chemotherapy impacts overall survival in pancreatic cancer","volume":"27","author":"Ghabi","year":"2023","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"10.1016\/j.gassur.2026.102358_bib32","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.surg.2024.01.008","article-title":"Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: a retrospective multi-institutional analysis","volume":"175","author":"Shimizu","year":"2024","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.gassur.2026.102358_bib33","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1245\/s10434-021-11202-8","volume":"29","author":"Hill","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2026.102358_bib34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ijrobp.2010.10.011","article-title":"CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer","volume":"81","author":"Kim","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.gassur.2026.102358_bib35","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1245\/s10434-014-3607-8","article-title":"Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer","volume":"21","author":"Combs","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102358_bib36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jso.26510","article-title":"Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma","volume":"124","author":"Narayanan","year":"2021","journal-title":"J Surg Oncol"},{"issue":"9","key":"10.1016\/j.gassur.2026.102358_bib37","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 Phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.gassur.2026.102358_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.6004\/jnccn.2022.7008","article-title":"Neoadjuvant radiotherapy after (m)FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: a TAPS consortium study","volume":"20","author":"Janssen","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.gassur.2026.102358_bib39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13014-019-1254-8","article-title":"Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)","volume":"14","author":"Gao","year":"2019","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102358_bib40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12885-021-08031-z","volume":"21","author":"Janssen","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.gassur.2026.102358_bib41","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1245\/s10434-022-12742-3","article-title":"A randomized, phase II, clinical trial of preoperative fractionated radiation therapy versus stereotactic body radiation therapy for resectable, borderline resectable, or locally advanced Type A pancreatic adenocarcinoma","volume":"30","author":"Saif","year":"2023","journal-title":"Ann Surg Oncol"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:24:37Z","timestamp":1773933877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X26000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1091255X26000399"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102358","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity score\u2013matched analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102358"}}